N‑glycosylation and receptor tyrosine kinase signaling affect claudin‑3 levels in colorectal cancer cells

Pérez,Amelia G.; Andrade‑Da‑Costa,Jéssica; De Souza,Waldemir F.; De Souza Ferreira,Michelle; Boroni,Mariana; De Oliveira,Ivanir M.; Freire‑Neto,Carlos A.; Fernandes,Priscila V.; De Lanna,Cristóvão A.; Souza‑Santos,Paulo Thiago; Morgado‑Díaz,José A.; De-Freitas‑Junior,Julio Cesar M.

doi:10.3892/or.2020.7727

N‑glycosylation and receptor tyrosine kinase signaling affect claudin‑3 levels in colorectal cancer cells

Authors:
- Amelia G. Pérez
- Jéssica Andrade‑Da‑Costa
- Waldemir F. De Souza
- Michelle De Souza Ferreira
- Mariana Boroni
- Ivanir M. De Oliveira
- Carlos A. Freire‑Neto
- Priscila V. Fernandes
- Cristóvão A. De Lanna
- Paulo Thiago Souza‑Santos
- José A. Morgado‑Díaz
- Julio Cesar M. De-Freitas‑Junior
View Affiliations

Affiliations: Cellular and Molecular Oncobiology Program, National Cancer Institute (INCA), Rio de Janeiro, RJ 20231‑050, Brazil, Bioinformatics and Computational Biology Laboratory, National Cancer Institute (INCA), Rio de Janeiro, RJ 20231‑050, Brazil, Pathology Division, National Cancer Institute (INCA), Rio de Janeiro, RJ 20231‑050, Brazil, Leprosy Laboratory, Oswaldo Cruz Institute (IOC), Rio de Janeiro, RJ 21041‑361, Brazil
Published online on: August 11, 2020 https://doi.org/10.3892/or.2020.7727
Pages: 1649-1661
Copyright: © Pérez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Changes in protein levels in different components of the apical junctional complex occur in colorectal cancer (CRC). Claudin‑3 is one of the main constituents of tight junctions, and its overexpression can increase the paracellular flux of macromolecules, as well as the malignant potential of CRC cells. The aim of this study was to investigate the molecular mechanisms involved in the regulation of claudin‑3 and its prognostic value in CRC. In silico evaluation in each of the CRC consensus molecular subtypes (CMSs) revealed that high expression levels of CLDN3 (gene encoding claudin‑3) in CMS2 and CMS3 worsened the patients' long‑term survival, whereas a decrease in claudin‑3 levels concomitant with a reduction in phosphorylation levels of epidermal growth factor receptor (EGFR) and insulin‑like growth factor 1 receptor (IGF1R) could be achieved by inhibiting N‑glycan biosynthesis in CRC cells. We also observed that specific inactivation of these receptor tyrosine kinases (RTKs) led to a decrease in claudin‑3 levels, and this regulation seems to be mediated by phospholipase C (PLC) and signal transducer and activator of transcription 3 (STAT3) in CRC cells. RTKs are modulated by their N‑linked glycans, and inhibition of N‑glycan biosynthesis decreased the claudin‑3 levels; therefore, we evaluated the correlation between N‑glycogenes and CLDN3 expression levels in each of the CRC molecular subtypes. The CMS1 (MSI immune) subtype concomitantly exhibited low expression levels of CLDN3 and N‑glycogenes (MGAT5, ST6GAL1, and B3GNT8), whereas CMS2 (canonical) exhibited high gene expression levels of CLDN3 and N‑glycogenes (ST6GAL1 and B3GNT8). A robust positive correlation was also observed between CLDN3 and B3GNT8 expression levels in all CMSs. These results support the hypothesis of a mechanism integrating RTK signaling and N‑glycosylation for the regulation of claudin‑3 levels in CRC, and they suggest that CLDN3 expression can be used to predict the prognosis of patients identified as CMS2 or CMS3.

View Figures

View References

1	IJspeert JE, Vermeulen L, Meijer GA and Dekker E: Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol. 12:401–409. 2015. View Article : Google Scholar : PubMed/NCBI
2	Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
3	Fessler E, Drost J, van Hooff SR, Linnekamp JF, Wang X, Jansen M, De Sousa E, Melo F, Prasetyanti PR, IJspeert JE, et al: TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol Med. 8:745–760. 2016. View Article : Google Scholar : PubMed/NCBI
4	Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al: The consensus molecular subtypes of colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
5	Bramsen JB, Rasmussen MH, Ongen H, Mattesen TB, Ørntoft MW, Árnadóttir SS, Sandoval J, Laguna T, Vang S, Øster B, et al: Molecular-subtype-specific biomarkers improve prediction of prognosis in colorectal cancer. Cell Rep. 19:1268–1280. 2017. View Article : Google Scholar : PubMed/NCBI
6	Gehren AS, Rocha MR, de Souza WF and Morgado-Díaz JA: Alterations of the apical junctional complex and actin cytoskeleton and their role in colorectal cancer progression. Tissue Barriers. 3:e10176882015. View Article : Google Scholar : PubMed/NCBI
7	Lingaraju A, Long TM, Wang Y, Austin JR II and Turner JR: Conceptual barriers to understanding physical barriers. Semin Cell Dev Biol. 42:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zihni C, Mills C, Matter K and Balda MS: Tight junctions: From simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 17:564–580. 2016. View Article : Google Scholar : PubMed/NCBI
9	de Oliveira SS, de Oliveira IM, De Souza W and Morgado-Díaz JA: Claudins upregulation in human colorectal cancer. FEBS Lett. 579:6179–6185. 2005. View Article : Google Scholar : PubMed/NCBI
10	Krug SM, Schulzke JD and Fromm M: Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol. 36:166–176. 2014. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Sun T, Sun H, Yang S, Li D and Zhou D: SCF/C-Kit/JNK/AP-1 signaling pathway promotes claudin-3 expression in colonic epithelium and colorectal carcinoma. Int J Mol Sci. 18:7652017. View Article : Google Scholar
12	de Souza WF, Fortunato-Miranda N, Robbs BK, de Araujo WM, de-Freitas-Junior JC, Bastos LG, Viola JP and Morgado-Díaz JA: Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: Roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PLoS One. 8:e749942013. View Article : Google Scholar : PubMed/NCBI
13	Singh AB and Harris RC: Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in madin-darby canine kidney cells. J Biol Chem. 279:3543–3552. 2004. View Article : Google Scholar : PubMed/NCBI
14	Ikari A, Sato T, Watanabe R, Yamazaki Y and Sugatani J: Increase in claudin-2 expression by an EGFR/MEK/ERK/c-fos pathway in lung adenocarcinoma A549 cells. Biochim Biophys Acta. 1823:1110–1118. 2012. View Article : Google Scholar : PubMed/NCBI
15	Campbell HK, Maiers JL and DeMali KA: Interplay between tight junctions & adherens junctions. Exp Cell Res. 358:39–44. 2017. View Article : Google Scholar : PubMed/NCBI
16	Nita-Lazar M, Rebustini I, Walker J and Kukuruzinska MA: Hypoglycosylated E-cadherin promotes the assembly of tight junctions through the recruitment of PP2A to adherens junctions. Exp Cell Res. 316:1871–1884. 2010. View Article : Google Scholar : PubMed/NCBI
17	Fernandes H, Cohen S and Bishayee S: Glycosylation-induced conformational modification positively regulates receptor- receptor association: A study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem. 276:5375–5383. 2001. View Article : Google Scholar : PubMed/NCBI
18	Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, Johns TG, Beth AH and Staros JV: Functional effects of glycosylation at asn-579 of the epidermal growth factor receptor. Biochemistry. 44:14920–14931. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kaszuba K, Grzybek M, Orłowski A, Danne R, Róg T, Simons K, Coskun Ü and Vattulainen I: N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Proc Natl Acad Sci USA. 112:4334–4339. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lopez Sambrooks C, Baro M, Quijano A, Narayan A, Cui W, Greninger P, Egan R, Patel A, Benes CH, Saltzman WM and Contessa JN: Oligosaccharyltransferase inhibition overcomes therapeutic resistance to EGFR tyrosine kinase inhibitors. Cancer Res. 78:5094–5106. 2018. View Article : Google Scholar : PubMed/NCBI
21	Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M and Dennis JW: Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 129:123–134. 2007. View Article : Google Scholar : PubMed/NCBI
22	Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al: TCGAbiolinks: An R/bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44:e712016. View Article : Google Scholar : PubMed/NCBI
23	de Freitas Junior JC, Silva BR, de Souza WF, de Araújo WM, Abdelhay ES and Morgado-Díaz JA: Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell-cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells. Cancer Chemother Pharmacol. 68:227–238. 2011. View Article : Google Scholar : PubMed/NCBI
24	Peter Y, Comellas A, Levantini E, Ingenito EP and Shapiro SD: Epidermal growth factor receptor and claudin-2 participate in A549 permeability and remodeling: Implications for non-small cell lung cancer tumor colonization. Mol Carcinog. 48:488–497. 2009. View Article : Google Scholar : PubMed/NCBI
25	Taniguchi N and Korekane H: Branched N-glycans and their implications for cell adhesion, signaling and clinical applications for cancer biomarkers and in therapeutics. BMB Rep. 44:772–781. 2011. View Article : Google Scholar : PubMed/NCBI
26	Ishida H, Togayachi A, Sakai T, Iwai T, Hiruma T, Sato T, Okubo R, Inaba N, Kudo T, Gotoh M, et al: A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett. 579:71–78. 2005. View Article : Google Scholar : PubMed/NCBI
27	Dall'Olio F, Malagolini N, di Stefano G, Minni F, Marrano D and Serafini-Cessi F: Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues. Int J Cancer. 44:434–439. 1989. View Article : Google Scholar : PubMed/NCBI
28	Petretti T, Kemmner W, Schulze B and Schlag PM: Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut. 46:359–366. 2000. View Article : Google Scholar : PubMed/NCBI
29	Dall'Olio F, Chiricolo M, Ceccarelli C, Minni F, Marrano D and Santini D: Beta-galactoside alpha2,6 sialyltransferase in human colon cancer: Contribution of multiple transcripts to regulation of enzyme activity and reactivity with sambucus nigra agglutinin. Int J Cancer. 88:58–65. 2000. View Article : Google Scholar : PubMed/NCBI
30	Dall'Olio F, Chiricolo M, Mariani E and Facchini A: Biosynthesis of the cancer-related sialyl-alpha 2,6-lactosaminyl epitope in colon cancer cell lines expressing beta-galactoside alpha 2,6-sialyltransferase under a constitutive promoter. Eur J Biochem. 268:5876–5884. 2001. View Article : Google Scholar : PubMed/NCBI
31	Royer C and Lu X: Epithelial cell polarity: A major gatekeeper against cancer? Cell Death Differ. 18:1470–1477. 2011. View Article : Google Scholar : PubMed/NCBI
32	Halaoui R and McCaffrey L: Rewiring cell polarity signaling in cancer. Oncogene. 34:939–950. 2015. View Article : Google Scholar : PubMed/NCBI
33	Bouchagier KA, Assimakopoulos SF, Karavias DD, Maroulis I, Tzelepi V, Kalofonos H, Karavias DD, Kardamakis D, Scopa CD and Tsamandas AC: Expression of claudins-1, −4, −5, −7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. In Vivo. 28:315–326. 2014.PubMed/NCBI
34	Katayama A, Handa T, Komatsu K, Togo M, Horiguchi J, Nishiyama M and Oyama T: Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome. Pathol Int. 67:404–413. 2017. View Article : Google Scholar : PubMed/NCBI
35	Pinho SS, Figueiredo J, Cabral J, Carvalho S, Dourado J, Magalhães A, Gärtner F, Mendonfa AM, Isaji T, Gu J, et al: E-cadherin and adherens-junctions stability in gastric carcinoma: Functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta. 1830:2690–2700. 2013. View Article : Google Scholar : PubMed/NCBI
36	Bücker R, Krug SM, Fromm A, Nielsen HL, Fromm M, Nielsen H and Schulzke JD: Campylobacter fetus impairs barrier function in HT-29/B6 cells through focal tight junction alterations and leaks. Ann N Y Acad Sci. 1405:189–201. 2017. View Article : Google Scholar : PubMed/NCBI
37	Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M and Schulzke JD: Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active crohn's disease. Gut. 56:61–72. 2007. View Article : Google Scholar : PubMed/NCBI
38	Nami B, Donmez H and Kocak N: Tunicamycin-induced endoplasmic reticulum stress reduces in vitro subpopulation and invasion of CD44⁺/CD24⁻ phenotype breast cancer stem cells. Exp Toxicol Pathol. 68:419–426. 2016. View Article : Google Scholar : PubMed/NCBI
39	Capaldo CT and Nusrat A: Claudin switching: Physiological plasticity of the tight junction. Semin Cell Dev Biol. 42:22–29. 2015. View Article : Google Scholar : PubMed/NCBI
40	Findley MK and Koval M: Regulation and roles for claudin-family tight junction proteins. IUBMB Life. 61:431–437. 2009. View Article : Google Scholar : PubMed/NCBI
41	Koval M: Differential pathways of claudin oligomerization and integration into tight junctions. Tissue Barriers. 1:e245182013. View Article : Google Scholar : PubMed/NCBI
42	Hewitt KJ, Agarwal R and Morin PJ: The claudin gene family: Expression in normal and neoplastic tissues. BMC Cancer. 6:1862006. View Article : Google Scholar : PubMed/NCBI
43	Kwon MJ: Emerging roles of claudins in human cancer. Int J Mol Sci. 14:18148–18180. 2013. View Article : Google Scholar : PubMed/NCBI
44	Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, Levine M, Whelan T and Bane AL: Claudin-low breast cancer; clinical & pathological characteristics. PLoS One. 12:e01686692017. View Article : Google Scholar : PubMed/NCBI
45	Oliveira SS and Morgado-Díaz JA: Claudins: Multifunctional players in epithelial tight junctions and their role in cancer. Cell Mol Life Sci. 64:17–28. 2007. View Article : Google Scholar : PubMed/NCBI
46	Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, et al: Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 160:1239–1249. 2002. View Article : Google Scholar : PubMed/NCBI
47	Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P and Miller LD: Prognostic molecular subtypes of low-grade cancer of the appendix. J Am Coll Surg. 222:493–503. 2016. View Article : Google Scholar : PubMed/NCBI
48	Ashkani J and Naidoo KJ: Glycosyltransferase gene expression profiles classify cancer types and propose prognostic subtypes. Sci Rep. 6:264512016. View Article : Google Scholar : PubMed/NCBI
49	Thanki K, Nicholls ME, Gajjar A, Senagore AJ, Qiu S, Szabo C, Hellmich MR and Chao C: Consensus molecular subtypes of colorectal cancer and their clinical implications. Int Biol Biomed J. 3:105–111. 2017.PubMed/NCBI
50	Cherradi S, Martineau P, Gongora C and Del Rio M: Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype. Cancer Manag Res. 11:1337–1348. 2019. View Article : Google Scholar : PubMed/NCBI
51	Vogel C and Marcotte EM: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 13:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
52	Koussounadis A, Langdon SP, Um IH, Harrison DJ and Smith VA: Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci Rep. 5:107752015. View Article : Google Scholar : PubMed/NCBI
53	Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, O'Grady T, Arthur K, Loughrey MB, Allen WL, et al: Challenging the cancer molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin Cancer Res. 22:4095–4104. 2016. View Article : Google Scholar : PubMed/NCBI
54	Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M: Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 24 (Suppl 2):S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI
55	De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, et al: Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 19:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
56	Trinh A, Trumpi K, De Sousa E, Melo F, Wang X, de Jong JH, Fessler E, Kuppen PJ, Reimers MS, Swets M, et al: Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin Cancer Res. 23:387–398. 2017. View Article : Google Scholar : PubMed/NCBI
57	Carvalho S, Reis CA and Pinho SS: Cadherins glycans in cancer: Sweet players in a bitter process. Trends Cancer. 2:519–531. 2016. View Article : Google Scholar : PubMed/NCBI
58	Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A and Lawrence TS: Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res. 16:3205–3214. 2010. View Article : Google Scholar : PubMed/NCBI
59	de Freitas Junior JC and Morgado-Díaz JA: The role of N-glycans in colorectal cancer progression: Potential biomarkers and therapeutic applications. Oncotarget. 7:19395–19413. 2016. View Article : Google Scholar : PubMed/NCBI
60	Anugraham M, Jacob F, Nixdorf S, Everest-Dass AV, Heinzelmann-Schwarz V and Packer NH: Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: Glycan structures reflect gene expression and DNA methylation status. Mol Cell Proteomics. 13:2213–2232. 2014. View Article : Google Scholar : PubMed/NCBI
61	Kannagi R, Yin J, Miyazaki K and Izawa M: Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim Biophys Acta. 1780:525–531. 2008. View Article : Google Scholar : PubMed/NCBI
62	Meany DL and Chan DW: Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 8:72011. View Article : Google Scholar : PubMed/NCBI
63	Liu L, Yan B, Huang J, Gu Q, Wang L, Fang M, Jiao J and Yue X: The identification and characterization of novel N-glycan-based biomarkers in gastric cancer. PLoS One. 8:e778212013. View Article : Google Scholar : PubMed/NCBI
64	Qin R, Zhao J, Qin W, Zhang Z, Zhao R, Han J, Yang Y, Li L, Wang X, Ren S, et al: Discovery of non-invasive glycan biomarkers for detection and surveillance of gastric cancer. J Cancer. 8:1908–1916. 2017. View Article : Google Scholar : PubMed/NCBI
65	Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, Jeon SK, Kim HC, Yoo JS and Ko JH: Overexpression and β-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: A ‘double whammy’ strategy in colon cancer progression. J Biol Chem. 287:32467–32478. 2012. View Article : Google Scholar : PubMed/NCBI
66	Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S, et al: Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res. 6:1772–1777. 2000.PubMed/NCBI